Evidence suggests that HYAL1 may inhibit CRC metastasis by modulating the balance between matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs), and by reorganizing the distribution of F-actin in the cytoskeleton [37,38]. Here, HYAL1 is linked to colorectal carcinoma.